Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sprifermin - Merck

Drug Profile

Sprifermin - Merck

Alternative Names: AS-902330; FGF-18; rhFGF-18; Zfgf5

Latest Information Update: 02 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Merck Serono; Molecular Therapeutics; Nordic Bioscience; Pfizer
  • Class Fibroblast growth factors; Neuroprotectants
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Cartilage disorders; Stroke

Most Recent Events

  • 10 Jan 2022 Sprifermin licensed to Trialspark worldwide
  • 15 Apr 2021 Sprifermin is still in phase II FORWARD trial for Osteoarthritis in Argentina, Czech Republic, Estonia, Denmark, Hong Kong, Poland, Romania and USA (Intra-articular) (NCT01919164)
  • 08 Oct 2019 Updated efficacy and adverse event data from the FORWARD phase II trial in Osteoarthritis presented in the Journal of the American Medical Association (JAMA)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top